Effect of Cabergoline on Weight and Glucose Tolerance

Columbia University

Status and phase: Completed; Phase 2; Phase 1

Conditions: Impaired Glucose Tolerance in Obese; Body Weight

Treatments: Other: placebo; Drug: Cabergoline

Study type: Interventional

Funder types: Other

Identifiers

NCT01395602

IRB #13952

Details and patient eligibility

About

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Enrollment: 40 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 18 - 55 years
• BMI 30 -40

Exclusion criteria

• diabetes,
• clinically significant medical condition,
• use of medications that effect blood glucose or body weight

Trial design

40 participants in 2 patient groups, including a placebo group

placebo

Placebo Comparator group

Description:

placebo pill

Treatment:

Other: placebo

cabergoline

Active Comparator group

Description:

cabergoline pill

Treatment:

Drug: Cabergoline